MF研究者総覧

教員活動データベース

A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan

発表形態:
資料・解説・論説・研究報告・総合雑誌の論文
主要業績:
主要業績
単著・共著:
共著
発表年月:
2021年02月
DOI:
10.1007/s12328-020-01260-y
会議属性:
指定なし
査読:
有り
リンク情報:

日本語フィールド

著者:
*Aiko Ikeuchi, Toshihiko Kakiuchi, Arisa Ibi, Muneaki Matsuo
題名:
A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan
発表情報:
Clin J Gastroenterol 巻: 14 号: 1 ページ: 146-151
キーワード:
Anti-TNF-failure; Child; Ulcerative colitis; Vedolizumab
概要:
Corticosteroids and biologics are used to treat moderate-to-severe active pediatric ulcerative colitis (UC); however, it is often difficult to continue administration because of systemic side reactions. Vedolizumab is considered to have few adverse effects due to its mechanism of action and it is expected to be used in children, but the long-term administration of vedolizumab to Japanese pediatric patients with UC has not been reported. We report a case of pediatric moderate active UC with anti-tumor necrosis factor-failure that was successfully treated with vedolizumab in Japan.
抄録:

英語フィールド

Author:
*Aiko Ikeuchi, Toshihiko Kakiuchi, Arisa Ibi, Muneaki Matsuo
Title:
A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan
Announcement information:
Clin J Gastroenterol Vol: 14 Issue: 1 Page: 146-151
Keyword:
Anti-TNF-failure; Child; Ulcerative colitis; Vedolizumab
An abstract:
Corticosteroids and biologics are used to treat moderate-to-severe active pediatric ulcerative colitis (UC); however, it is often difficult to continue administration because of systemic side reactions. Vedolizumab is considered to have few adverse effects due to its mechanism of action and it is expected to be used in children, but the long-term administration of vedolizumab to Japanese pediatric patients with UC has not been reported. We report a case of pediatric moderate active UC with anti-tumor necrosis factor-failure that was successfully treated with vedolizumab in Japan.


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.